TG Therapeutics (TGTX) has shared an announcement.
At the Company’s 2024 Annual Meeting, stockholders voted to expand the authorized shares of common stock, showcasing active investor participation with a quorum of over 71%. Key approvals included the election of six directors, the ratification of KPMG LLP as the independent auditor, executive compensation, and amendments to the Certificate of Incorporation and the 2022 Incentive Plan. These decisions reflect shareholder confidence and pave the way for the Company’s strategic growth initiatives.
See more data about TGTX stock on TipRanks’ Stock Analysis page.
